Rivaroxaban 2.5 MG Oral Tablet [Xarelto]
UW 20-312
Approved small_molecule completed
Quick answer
Rivaroxaban 2.5 MG Oral Tablet [Xarelto] for Atherosclerosis, Coronary is a Approved program (small_molecule) at The University of Hong Kong with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The University of Hong Kong
- Indication
- Atherosclerosis, Coronary
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed